AAV-Mediated TPP1 Delivery for CNS Lysosomal Storage Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods are ineffective in treating central nervous system (CNS) diseases like lysosomal storage diseases due to the inability of therapeutic proteins to cross the blood-brain barrier and achieve widespread distribution within the brain.
Innovation Solution
Administration of AAV particles encoding a polypeptide with lysosomal hydrolase activity, specifically tripeptidyl-peptidase 1 (TPP1), directly to the CNS using AAV particles comprising an AAV capsid protein, nucleic acid with TPP1 encoding, and expression control elements like CMV enhancer and beta actin promoter to ensure transduction and expression of the TPP1 enzyme.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If therapeutic proteins are delivered intravenously to treat CNS diseases, then the treatment can be administered systemically, but the proteins cannot cross the blood-brain barrier to reach the CNS
Solution Approach 1:
The patent uses AAV (adeno-associated virus) particles as intermediary carriers to deliver the TPP1 gene to CNS cells. The AAV particles can cross the blood-brain barrier and infect target cells, serving as a mediator between the therapeutic gene and the CNS tissue that cannot be reached by direct protein delivery.
2Reliability
If proteins are delivered directly to the brain, then the blood-brain barrier obstruction is avoided, but the proteins are not widely distributed throughout the CNS
Solution Approach 1:
The patent employs the cell's own transcriptional and translational machinery to produce the therapeutic TPP1 protein. After AAV-mediated gene delivery, the introduced TPP1 gene is transcribed and translated by the infected cells themselves, enabling widespread and sustained production of the enzyme throughout the CNS rather than relying on external protein delivery.
3Reliability
If gene therapy is used to treat lysosomal storage diseases, then the underlying genetic defect can be corrected, but the therapeutic gene cannot reach CNS cells due to the blood-brain barrier
Solution Approach 1:
The patent uses AAV particles as intermediary carriers to deliver the TPP1 gene to CNS cells. The AAV particles can cross the blood-brain barrier and infect target cells, serving as a mediator between the therapeutic gene and the CNS tissue that cannot be reached by direct protein delivery.
4Reliability
If AAV particles are administered to the CNS, then effective distribution of the TPP1 enzyme is achieved, but the complexity of the gene transfer composition increases
Solution Approach 1:
The patent uses a universal AAV vector system that can deliver the TPP1 gene to various CNS cell types. The AAV capsid provides universal entry capabilities, while the promoter elements (CMV enhancer, beta-actin promoter) provide universal transcriptional activation across different cell types, reducing the need for cell-type-specific customization.
Data Source
AI summary
Provided are methods of treating a lysosomal storage disorder in a mammal which method includes administering AAV particles encoding a polypeptide to the central nervous system of the mammal. AAV particles may be delivered by direct injection into the brain, spinal cord, cerebral spinal fluid or a portion thereof for expression.